Welcome to our dedicated page for enGene Holdings SEC filings (Ticker: ENGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for enGene Holdings Inc. (NASDAQ: ENGN), a British Columbia–incorporated, clinical-stage biotechnology company developing non-viral genetic medicines. Through these filings, investors can review how enGene reports clinical, regulatory, financial, and governance developments related to its lead program, detalimogene voraplasmid, and its broader corporate activities.
enGene’s current reports on Form 8-K provide detail on material events such as updated preliminary efficacy and safety data from the Phase 2 LEGEND trial in high-risk non-muscle invasive bladder cancer (NMIBC), changes to trial endpoints following discussions with the U.S. Food and Drug Administration, and enrollment status across LEGEND cohorts. Other 8-K filings describe executive and board appointments, amendments to executive employment agreements, and inducement equity awards granted under NASDAQ Listing Rule 5635(c)(4).
Filings also confirm that enGene’s common shares trade on The Nasdaq Stock Market LLC under the symbol ENGN, with warrants listed under ENGNW, and identify the company as an emerging growth company. Liquidity and capital structure information, including cash, cash equivalents and marketable securities balances and details of public offerings of common shares and pre-funded warrants, appear in financial disclosures and referenced exhibits.
On Stock Titan, users can access these SEC documents alongside AI-powered summaries that explain key points in clear language. Real-time updates from EDGAR surface new 8-Ks and other filings as they are submitted, while AI highlights sections related to clinical trial results, regulatory designations such as RMAT and Fast Track, manufacturing readiness programs like the FDA’s CDRP, and board or management changes. Form 4 insider transaction data, when filed, and periodic reports such as 10-K and 10-Q can be reviewed with AI-generated insights to help readers quickly understand complex regulatory and financial information.
enGene Holdings Inc. chief technology officer Joan Connolly received a stock option grant for 195,000 common shares on January 30, 2026. The options give her the right to buy these shares at an exercise price of $9.53 per share and expire on January 30, 2036.
The award vests monthly in substantially equal installments over 48 months, contingent on her continued service with the company. This Form 4 reports an incentive-based equity grant, with Connolly directly holding 195,000 derivative securities following the transaction.
enGene Holdings Inc. reported that Chief Regulatory Officer Boyd Matthew Ross received a grant of stock options on January 30, 2026. The award covers 195,000 stock options with an exercise price of $9.53 per common share and no upfront purchase price.
The options vest monthly in substantially equal installments over 48 months, as long as Ross continues his service with the company. Following this grant, Ross beneficially holds 195,000 derivative securities directly in the form of these options.
enGene Holdings Inc. disclosed that Chief Development Officer Jill Buck received a grant of stock options. On January 30, 2026, she was awarded 195,000 stock options with an exercise price of $9.53 per common share. These options were granted at no cost on the grant date and are held directly. The award vests monthly in substantially equal installments over 48 months, contingent on her continued service with the company, and represents her total reported derivative holdings after the transaction.
enGene Holdings Inc. received a Schedule 13G disclosure from a group of Invus-affiliated investment entities and Raymond Debbane reporting passive ownership of its common shares. As of January 27, 2026, Invus Public Equities, L.P. directly held 3,675,408 common shares and Avicenna Life Sci Master Fund LP directly held 569,151 common shares. Through their control relationships, Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master GP LLC, Ulys, L.L.C., and Mr. Debbane may each be deemed to beneficially own these holdings.
Mr. Debbane is reported as beneficial owner of 4,244,559 common shares, representing 6.3% of the class, based on 66,984,661 shares outstanding as of December 17, 2025. The reporting persons certify the shares were not acquired and are not held for the purpose of changing or influencing control of enGene, indicating a passive investment stance.
enGene Holdings Inc. entered into a Second Amendment to its loan and security agreement with Hercules Capital and other lenders, expanding its term loan facility from
The 2026 Term Loans mature on
enGene Holdings Inc. filed a current report describing a communication about its debt arrangements. The company announced that it entered into a Second Amendment to its Amended and Restated Loan and Security Agreement with Hercules Capital, Inc. and other lenders. This amendment builds on the original agreement dated December 22, 2023 and a prior amendment dated December 18, 2024, together referred to as the Amended Loan Agreement.
The company issued a press release on January 20, 2026 explaining the updated loan terms, which is furnished as an exhibit to the report rather than filed. As an emerging growth company with common shares and warrants listed on Nasdaq, enGene is using this report primarily to provide investors with notice of the press release and the existence of the amended loan agreement.
enGene Holdings Inc. (ENGN) launched a primary offering of 12,558,823 common shares and pre-funded warrants to purchase 2,735,295 common shares. The shares were priced at $8.50 and the pre-funded warrants at $8.4999 (with a $0.0001 exercise price). Gross proceeds are $129,999,729.47, with underwriting discounts of $7,800,000.18 and proceeds to enGene before expenses of $122,199,729.29. The underwriters have a 30-day option to buy up to 2,294,117 additional shares.
Net proceeds are estimated at approximately $121.77 million, or approximately $140.10 million if the option is fully exercised. The company plans to use the funds to advance clinical development of its lead gene therapy, detalimogene, prepare commercial infrastructure for a potential launch, and for general corporate purposes. Pre-funded warrants are immediately exercisable, do not expire, include a 9.99% beneficial ownership cap (adjustable up to 19.99% after 61 days), and will not be listed. Common shares outstanding were 52,019,362 as of November 11, 2025.
enGene Holdings Inc. (ENGN) launched a preliminary prospectus supplement for a primary offering of common shares pursuant to its shelf registration. The common shares trade on Nasdaq under “ENGN”; the last reported sale price was $8.82 per share on November 11, 2025.
The company plans to use net proceeds to fund continued clinical development of its lead gene therapy, detalimogene voraplasmid, prepare commercial infrastructure for a potential launch, and for general corporate purposes. As of October 31, 2025, cash, cash equivalents and short‑term investments were $202.4 million. The filing includes a 30‑day option for underwriters to purchase additional shares and a 90‑day lock‑up for the company, directors and officers. No sales will be made in Canada or knowingly to Canadian residents.
enGene is an emerging growth and smaller reporting company. In updated Phase 2 LEGEND data for BCG‑unresponsive NMIBC with CIS, Post‑Protocol Amendment Patients showed a complete response rate of 63% (any time; 95% CI: 51–74), 56% at 3 months (95% CI: 44–68) and 62% at 6 months (95% CI: 46–76). Shares outstanding were 52,019,362 as of November 11, 2025.
enGene Holdings Inc. reported updates from its ongoing Phase 2 LEGEND trial of detalimogene voraplasmid in high-risk, BCG‑unresponsive NMIBC. After discussions with the FDA, the pivotal cohort’s primary endpoint changed to complete response (CR) at any time, with duration of response as a key secondary endpoint. Cohort 1 completed enrollment of 125 patients.
Preliminary efficacy in the ITT subpopulations showed for Post‑Protocol Amendment Patients: CR rates of 63% (95% CI: 51–74) at any time, 56% at 3 months, and 62% at 6 months. For Pre‑Protocol Amendment Patients: 55% at any time, 55% at 3 months, and 41% at 6 months. Four Post‑Protocol patients without CR at 3 months converted to CR at 6 months.
Safety was favorable: among 125 patients, 42% experienced treatment‑related adverse events, mainly Grade 1/2; Grade 3 TRAEs occurred in 2.4%, with no Grade 4/5 reported. As of
enGene Holdings Inc. updated the employment agreement of executive Ronald H. W. Cooper. The Board of Directors, following a recommendation from its Compensation Committee, approved an amendment that increases his potential cash payout if his employment ends in connection with a change in control of the company.
Under the revised terms, if Mr. Cooper experiences a CIC Termination as defined in his agreement and complies with its conditions, he will receive a lump sum payment equal to 1.5x his annual target bonus, instead of the prior 1.0x multiple. This payment would be made within 45 days of the qualifying termination. The full amendment will be included as an exhibit to enGene’s Form 10-K for the fiscal year ending October 31, 2025.